Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Farkhanda Khan

Psychiatry Chandler, AZ Medical Doctor

NPI 1548437668 CMS profile 161440

3195 S Price Rd Ste 150, Chandler, AZ 85248

Open in the dashboard

General payments

$7,956

385 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Farkhanda Khan of Chandler, AZ is reported in the CMS Open Payments database as having received $7,956 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,026 42
2024 General $1,164 55
2023 General $962 40
2022 General $1,274 61
2021 General $1,692 88
2020 General $1,010 53
2019 General $828 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farkhanda Khan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Farkhanda Khan were reported at $1,026. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Farkhanda Khan Psychiatry median Middle half National median
2019 $828 $184 $59–$605 $163
2020 $1,010 $119 $36–$372 $114
2021 $1,692 $143 $43–$576 $132
2022 $1,274 $153 $50–$590 $149
2023 $962 $170 $56–$651 $160
2024 $1,164 $179 $57–$673 $164
2025 $1,026 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $1,074 44 payments
  2. UCB, Inc. $997 49 payments
  3. Eisai Inc. $912 45 payments
  4. Biohaven Pharmaceuticals, Inc. $438 27 payments
  5. Pfizer Inc. $389 20 payments
  6. Lilly USA, LLC $349 18 payments
  7. Harmony Biosciences LLC $343 13 payments
  8. SK Life Science, Inc. $275 12 payments
  9. EMD Serono, Inc. $269 14 payments
  10. Teva Pharmaceuticals USA, Inc. $256 12 payments
  11. Other $2,654 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,956 385 payments
Products named General payments · program years 2019–2025
  1. XYWAV $809 31 payments
  2. Leqembi $770 38 payments
  3. NURTEC ODT Primary Care $661 41 payments
  4. Neupro $494 29 payments
  5. ZAVZPRET $389 20 payments
  6. Briviact $287 13 payments
  7. NURTEC ODT Pain $281 19 payments
  8. EMGALITY $279 15 payments
  9. REYVOW $270 14 payments
  10. Wakix $224 9 payments
  11. Other $4,347 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

241

Median for Psychiatry & Neurology: 100

Drug cost

$4,800

Median for Psychiatry & Neurology: $2,986

Branded share of claims

6.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 23 $1,120
Mirtazapine Generic 25 $823
Lorazepam Generic 50 $787
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 16 $687
Gabapentin Generic 14 $485
Quetiapine Fumarate Generic 16 $366
Zolpidem Tartrate Generic 29 $248
Clonazepam Generic 41 $151
Alprazolam Generic 27 $132

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $434
$434 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $162
$162 — —
Nayzilam
  • UCB, Inc. $88
$88 — —
NURTEC ODT
  • PFIZER INC. $67
$67 — —
ZAVZPRET
  • PFIZER INC. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record